Determining immunoassay cutoff value using Western blot results to predict hepatitis C infection in blood donors with low-titer anti-HCV reactivity
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu hodnotící studie, časopisecké články
- MeSH
- chronická hepatitida C diagnóza imunologie MeSH
- Hepacivirus imunologie MeSH
- hepatitida C - protilátky krev MeSH
- klinické laboratorní techniky metody normy MeSH
- lidé MeSH
- prediktivní hodnota testů MeSH
- senzitivita a specificita MeSH
- western blotting metody MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- hodnotící studie MeSH
- Názvy látek
- hepatitida C - protilátky MeSH
Since the 1990s, blood donors have been scanned for anti-hepatitis C virus (anti-HCV) antibodies, which can be defined by enzyme immunoassay as a screening test. In this population, false-reactive ratios have been high. Recently, some authors have aimed to find a cutoff value for anti-HCV different from those established by test manufacturers to predict HCV infection. In this study, 321 patients, after two repeating tests, had reactive results in s/co <10 titers on anti-HCV test. The patients were 29.6 % (n = 95) in women and 70.4 % (n = 226) in men. The patients were classified into three groups by Western blot (WB) results (PS, positive; NG, negative; and ID, indeterminate). The average anti-HCV titer of the whole group was 2.61 ± 1.96. Anti-HCV titers of subgroups were 2.43 ± 1.95 in NG, 4.93 ± 2.53 in PS, and 2.50 ± 1.65 in ID (p < 0.001). There was a significant difference between NG and PS and between PS and ID subgroups (p < 0.001). There was a positive correlation between WB and anti-HCV titers in all patients (r = 0.298, p < 0.001), in women (r = 0.282, p < 0.001), and in men (r = 0.337, p = 0.002). According to receiver operator characteristic curve analysis, the cutoff value of anti-HCV titer to predict hepatitis C infection was >2.61 s/co, with 74.1 % sensitivity and 71.6 % specificity (area under the curve, 0.820; 95 % confidence interval, 0.753 to 0.887). We suggest that an effective cutoff value for anti-HCV other than that established by the manufacturer cannot be assigned to predict hepatitis C infection for blood donors in low-prevalence areas.
Zobrazit více v PubMed
Transfusion. 2008 Jun;48(6):1239-44 PubMed
Transfusion. 2000 May;40(5):580-4 PubMed
Int J Epidemiol. 1996 Jun;25(3):674-8 PubMed
MMWR Recomm Rep. 1998 Oct 16;47(RR-19):1-39 PubMed
Transfusion. 2003 Feb;43(2):226-34 PubMed
Clin Chem. 2003 Jun;49(6 Pt 1):940-4 PubMed
J Viral Hepat. 2001 Mar;8(2):87-95 PubMed
Transfusion. 2007 Sep;47(9):1686-90 PubMed
MMWR Recomm Rep. 2003 Feb 7;52(RR-3):1-13, 15; quiz CE1-4 PubMed
J Clin Virol. 2001 Jun;21(3):271-81 PubMed
J Clin Microbiol. 2005 May;43(5):2477-80 PubMed
Eur J Epidemiol. 2006;21(4):299-305 PubMed
